Compare FNWB & OKYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNWB | OKYO |
|---|---|---|
| Founded | 1923 | 2007 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 96.3M | 87.6M |
| IPO Year | 2012 | 2021 |
| Metric | FNWB | OKYO |
|---|---|---|
| Price | $10.94 | $1.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $13.50 | $6.33 |
| AVG Volume (30 Days) | 19.4K | ★ 59.0K |
| Earning Date | 04-29-2026 | 07-18-2025 |
| Dividend Yield | ★ 0.70% | N/A |
| EPS Growth | ★ 36.00 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $176,000.00 | N/A |
| Revenue This Year | $19.24 | N/A |
| Revenue Next Year | $8.90 | N/A |
| P/E Ratio | $275.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.13 | $1.34 |
| 52 Week High | $12.52 | $3.20 |
| Indicator | FNWB | OKYO |
|---|---|---|
| Relative Strength Index (RSI) | 39.65 | 42.89 |
| Support Level | $10.88 | $1.46 |
| Resistance Level | $10.94 | $1.72 |
| Average True Range (ATR) | 0.22 | 0.10 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 3.33 | 23.64 |
First Northwest Bancorp is a bank holding company and a financial holding company and is engaged in banking activities through its wholly owned subsidiary, First Fed Bank, as well as certain non-banking financial activities. It offers various products and services, such as commercial business loans, multi-family real estate loans, auto and consumer loans, transaction accounts, savings and money market accounts, online banking services, etc., focused on the lending, deposit, and money movement needs of individuals, businesses and nonprofit organizations. The Group's operations are mainly focused on serving various communities in Washington State, U.S. Substantially all of its income is derived from a diverse base of commercial, mortgage, and consumer lending activities and investments.
OKYO Pharma Ltd is a clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. It is advancing a pipeline designed to improve outcomes for patients suffering from debilitating ocular diseases that impact vision and ocular comfort. The company's main program, urcosimod, is being developed as a potential treatment for neuropathic corneal pain. Additionally, its development pipeline includes an exploratory candidate, OK-201, a non-opioid analgesic drug candidate, as a potential drug to treat acute and chronic ocular pain. The company has only one operating segment: the research and development of biotechnological and pharmaceutical products.